- Home
- SACH vs OPTN Comparison
SACH vs OPTN Comparison
Compare SACH & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- OPTN
- Stock Information
- Founded
- SACH 2010
- OPTN 2010
- Country
- SACH United States
- OPTN United States
- Employees
- SACH N/A
- OPTN N/A
- Industry
- SACH Real Estate Investment Trusts
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- OPTN Health Care
- Exchange
- SACH Nasdaq
- OPTN Nasdaq
- Market Cap
- SACH 114.0M
- OPTN 117.6M
- IPO Year
- SACH 2017
- OPTN 2017
- Fundamental
- Price
- SACH $2.45
- OPTN $0.66
- Analyst Decision
- SACH Strong Buy
- OPTN Strong Buy
- Analyst Count
- SACH 2
- OPTN 2
- Target Price
- SACH $4.25
- OPTN $4.00
- AVG Volume (30 Days)
- SACH 237.8K
- OPTN 504.8K
- Earning Date
- SACH 11-11-2024
- OPTN 11-07-2024
- Dividend Yield
- SACH 16.94%
- OPTN N/A
- EPS Growth
- SACH N/A
- OPTN N/A
- EPS
- SACH 0.05
- OPTN N/A
- Revenue
- SACH $21,298,064.00
- OPTN $75,058,000.00
- Revenue This Year
- SACH N/A
- OPTN $24.44
- Revenue Next Year
- SACH N/A
- OPTN $49.00
- P/E Ratio
- SACH $47.18
- OPTN N/A
- Revenue Growth
- SACH N/A
- OPTN 3.91
- 52 Week Low
- SACH $2.22
- OPTN $0.65
- 52 Week High
- SACH $4.64
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- SACH 43.29
- OPTN 30.20
- Support Level
- SACH $2.38
- OPTN $0.65
- Resistance Level
- SACH $2.46
- OPTN $0.74
- Average True Range (ATR)
- SACH 0.07
- OPTN 0.04
- MACD
- SACH -0.02
- OPTN 0.00
- Stochastic Oscillator
- SACH 18.18
- OPTN 22.50
About SACH Sachem Capital Corp.
Sachem Capital Corp is a United States-based real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.